This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Feb 19;377(9766):635-6, author reply 636-7.

doi: 10.1016/S0140-6736(11)60224-9.

Paricalcitol for reduction of albuminuria in diabetes

Alberto Ortiz, Maria Dolores Sanchez Niño, Jorge Rojas, Jesus Egido

PMID: 21334525
DOI: 10.1016/S0140-6736(11)60224-9

Free article

Comment

Paricalcitol for reduction of albuminuria in diabetes

Alberto Ortiz et al. Lancet. 2011.

Free article

. 2011 Feb 19;377(9766):635-6, author reply 636-7.

doi: 10.1016/S0140-6736(11)60224-9.

Authors

Alberto Ortiz, Maria Dolores Sanchez Niño, Jorge Rojas, Jesus Egido

PMID: 21334525
DOI: 10.1016/S0140-6736(11)60224-9

No abstract available

PubMed Disclaimer

Comment on

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. de Zeeuw D, et al. Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X. Lancet. 2010. PMID: 21055801 Clinical Trial.

Similar articles

Paricalcitol for reduction of albuminuria in diabetes.
Delanaye P, Mariat C, Krzesinski JM, Cavalier E. Delanaye P, et al. Lancet. 2011 Feb 19;377(9766):635, author reply 636-7. doi: 10.1016/S0140-6736(11)60222-5. Lancet. 2011. PMID: 21334526 No abstract available.
Paricalcitol for reduction of albuminuria in diabetes.
Fourtounas C. Fourtounas C. Lancet. 2011 Feb 19;377(9766):636, author reply 636-7. doi: 10.1016/S0140-6736(11)60225-0. Lancet. 2011. PMID: 21334527 No abstract available.
Paricalcitol for reduction of albuminuria in diabetes.
Kassimatis T. Kassimatis T. Lancet. 2011 Feb 19;377(9766):635, author reply 636-7. doi: 10.1016/S0140-6736(11)60223-7. Lancet. 2011. PMID: 21334524 No abstract available.
[Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
Mascia S, Garofalo C, Donnarumma G, Di Pietro R, Liberti ME, Pacilio M, Sagliocca A, Zamboli P, Minutolo R, Conte G, De Nicola L. Mascia S, et al. G Ital Nefrol. 2010 Nov-Dec;27(6):616-28. G Ital Nefrol. 2010. PMID: 21132644 Review. Italian.
The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.
Duplancic D, Cesarik M, Poljak NK, Radman M, Kovacic V, Radic J, Rogosic V. Duplancic D, et al. Clin Interv Aging. 2013;8:149-56. doi: 10.2147/CIA.S38349. Epub 2013 Feb 11. Clin Interv Aging. 2013. PMID: 23430986 Free PMC article. Review.

See all similar articles

Cited by

A commentary on the VITAL study: Does vitamin D (receptor activation) protect against nephropathy in type 2 diabetes?
Okada S, Shikata K. Okada S, et al. J Diabetes Investig. 2012 Feb 20;3(1):36-8. doi: 10.1111/j.2040-1124.2011.00161.x. J Diabetes Investig. 2012. PMID: 24843543 Free PMC article. No abstract available.
TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease.
Rayego-Mateos S, Morgado-Pascual JL, Valdivielso JM, Sanz AB, Bosch-Panadero E, Rodrigues-Díez RR, Egido J, Ortiz A, González-Parra E, Ruiz-Ortega M. Rayego-Mateos S, et al. J Am Soc Nephrol. 2020 Sep;31(9):2026-2042. doi: 10.1681/ASN.2019111206. Epub 2020 Jul 6. J Am Soc Nephrol. 2020. PMID: 32631974 Free PMC article.
Vitamin D deficiency and related risk factors in patients with diabetic nephropathy.
Xiao X, Wang Y, Hou Y, Han F, Ren J, Hu Z. Xiao X, et al. J Int Med Res. 2016 Jun;44(3):673-84. doi: 10.1177/0300060515593765. Epub 2016 Mar 4. J Int Med Res. 2016. PMID: 26944386 Free PMC article.
Effect of Vitamin D on Urinary Angiotensinogen Level in Early Diabetic Nephropathy.
Mahapatra HS, Kumar A, Kulshreshtha B, Chitkara A, Kumari A. Mahapatra HS, et al. Indian J Nephrol. 2021 Jul-Aug;31(4):341-348. doi: 10.4103/ijn.IJN_67_20. Epub 2021 Jan 27. Indian J Nephrol. 2021. PMID: 34584348 Free PMC article.
Therapeutic approaches to diabetic nephropathy--beyond the RAS.
Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Fernandez-Fernandez B, et al. Nat Rev Nephrol. 2014 Jun;10(6):325-46. doi: 10.1038/nrneph.2014.74. Epub 2014 May 6. Nat Rev Nephrol. 2014. PMID: 24802062 Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information